A Phase IIIb Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous (SC) Tocilizumab (TCZ) Given as Monotherapy or in Combination With Methotrexate (MTX) or Other Non Biologics DMARDs in Subjects With Rheumatoid Arthritis
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms TOZURA
- Sponsors Roche
- 06 Apr 2018 Results (n=1804) of pooled data from 11 clinical trials assessing the efficacy, safety and immunogenicity of TCZ-SC 162 mg qw as monotherapy and in combination with csDMARDs over 24 weeks in adult patients with moderate to severe RA in a broad geographic setting, were published in the Rheumatology.
- 13 Dec 2017 Results (n=1804) of pooled analysis of TOZURA study programme of this and other ten studies assessing efficacy, safety and immunogenecity, published in the Rheumatology.
- 17 Jun 2017 Results of pooled analysis, presented at the 18th Annual Congress of the European League Against Rheumatism